The Orvida clinical trial for Olmsted Syndrome (TRPV3-pEDD and PERP-pEDD) has begun and is currently underway in the UK, France, and the US. We extend a big shout-out to our OS registry patients who are making significant sacrifices to be among the first participants in this study evaluating a new treatment.
The PC clinical trial – using the same medication – is expected to begin in early 2027.
PC Project, along with our key clinical collaborators, continues to work closely with Orvida in planning for this next phase. Much of the progress to date has been made possible by patients who participated in the pilot study in London in June 2025, helping refine methods to determine whether a drug is working. We are also grateful to those patients who continue to complete surveys and test wearable devices, contributing valuable real-world data.
As trial preparations continue, we will keep our patient community informed about opportunities to participate in both the OS and PC clinical trials
